Effect of N-homocysteinylation on physicochemical and cytotoxic properties of amyloid β-peptide  by Khodadadi, Sirus et al.
FEBS Letters 586 (2012) 127–131journal homepage: www.FEBSLetters .orgEffect of N-homocysteinylation on physicochemical and cytotoxic properties
of amyloid b-peptide
Sirus Khodadadi a, Gholam Hossein Riazi a,⇑, Shahin Ahmadian a, Elham Hoveizi b, Oveis Karima a,
Hassan Aryapour c
a Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
bDepartment of Biology, Faculty of Sciences, University of Tarbiat Moallem, Tehran, Iran
cDepartment of Biochemistry, Islamic Azad University, Sanandaj Branch, Sanandaj, Irana r t i c l e i n f o
Article history:
Received 1 November 2011
Revised 30 November 2011
Accepted 14 December 2011
Available online 23 December 2011
Edited by Jesus Avila
Keywords:
Alzheimer’s disease
Amyloid b-peptide
N-Homocysteinylation
Aggregation0014-5793/$36.00  2011 Federation of European Bio
doi:10.1016/j.febslet.2011.12.018
Abbreviations: AD, Alzheimer’s disease; Ab, amylo
teine; HCTL, homocysteine thiolactone; ThT, thioﬂav
TEM, transmission electron microscopy; LDH, lactate
dimethylthiazol-2-y]-2,5-diphenyl tetrazolium bromi
⇑ Corresponding author. Fax: +98 21 66404680.
E-mail address: riazi@ibb.ut.ac.ir (G.H. Riazi).a b s t r a c t
Hyperhomocysteinemia has recently been identiﬁed as an important risk factor for Alzheimer’s dis-
ease (AD). One of the potential mechanisms underlying harmful effects of homocysteine (Hcy) is
site-speciﬁc acylation of proteins at lysine residues by homocysteine thiolactone (HCTL). The accu-
mulation of amyloid b-peptide (Ab) in the brain is a neuropathological hallmark of AD. In the pres-
ent study we were interested to investigate the effects of N-homocysteinylation on the aggregation
propensity and neurotoxicity of Ab1–42. By coupling several techniques, we demonstrated that the
homocysteinylation of lysine residues increase the neurotoxicity of the Ab peptide by stabilizing sol-
uble oligomeric intermediates.
Structured summary of protein interactions:
A Beta 1-42 and A Beta 1-42 bind by ﬂuorescence technology (View interaction)
A Beta 1-42 and A Beta 1-42 bind by electron microscopy (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction a thiol group. This causes large changes in structure and biochemicalElevated plasma level of homocysteine (hyperhomocystein-
emia) has recently been identiﬁed as an independent risk factor
for the development of cardiovascular diseases and neurodegener-
ative disorders (Dementia, Alzheimer’s disease, Schizophrenia)
[1–4]. Several studies have shown that one of the likely mecha-
nisms underlying harmful effects of homocysteine (Hcy) is a chem-
ical modiﬁcation of protein by homocysteine thiolactone (HCTL), a
highly reactive cyclic thioester of Hcy [5–8], which is formed by
methionyl-tRNA synthetase [5,6,9] in the human body [10,11]
and is greatly elevated in CBS and MTHFR deﬁciencies [12].
It has been demonstrated that HCTL preferentially forms amide
bonds with e-amino group of protein lysine residues in a non-
enzymatic mechanism; a process referred to as ‘‘protein N-
homocysteinylation’’ [13]. Thismodiﬁcationneutralizes thepositive
charge of the e-aminogroupof protein lysine residue and introduceschemical Societies. Published by E
id b-peptide; Hcy, homocys-
in T; CD, circular dichroism;
dehydrogenase; MTT, 3-[4,5-
deproperties of the protein [7,8,14].
Alzheimer’s disease (AD), the most common age-related neuro-
degenerative disorder, is a progressive disease that results in the
death of speciﬁc neuronal populations and a devastating loss of
cognitive function. It is well known that aggregation of amyloid
b-peptide (Ab) plays a central role in mediating neurotoxicity in
AD [15–17].
Ab is a normal product of cellular metabolism which has been
implicated in numerous physiological activities including cell sur-
vival and synaptic activity [18]. It is a 39–43 amino acid peptide gen-
erated by sequential proteolytic cleavage of the transmembrane
amyloid precursor protein (APP) catalyzed by b- and c-secretases
[19]. The concentration and physicochemical properties of Ab spe-
cies and the relative abundance of Ab1–42 are the likely determinants
that switch its function from physiological to pathological [20].
The aggregation process involves formation of intermediate
oligomers that elongate to form ﬁbrils. In the ﬁrst ‘‘amyloid cas-
cade hypothesis’’, Ab ﬁbrils were supposed to be responsible for
the initiation of AD [19]. However, subsequent studies have shown
that neurological dysfunction and degeneration can be linked to
much smaller, oligomeric intermediates of Ab, which have now
been incorporated into a revised version of the amyloid cascade
hypothesis [21–23].lsevier B.V. All rights reserved.
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aggregation process and eventually in pathogenesis of AD. Previous
studies have demonstrated that the key aggregation motif of Ab
(16KLVFF20), in the central region, is an essential sequence but
not sufﬁcient for the self-assembly of Ab. Ab16–20 binds to the
homologous regions Ab17–21 or Ab18–22 and forms an antiparallel
b-sheet structure [24–27]. The 21–30 region of Ab (Ab21–30) is
another important sequence involved in the aggregation process.
The formation of b-turn structure in this region nucleates the fold-
ing process of Abmonomer, and initiates the molecular association
to form oligomeric intermediates [28–31]. The intra- or inter-
molecular salt bridge between Lys28 and Glu22/Asp23 in this
region is one of the important factors that contribute to the stabil-
ity of the turn [30,31].
Despite the proven increment of plasma homocysteine level
and its metabolite (HCTL) in AD, their effects on the Ab structure
and its neurotoxicity are not well understood [2]. The Ab is gener-
ally considered to be fully unfolded in the monomeric state in
aqueous solution [2,32] and therefore, its lysine residues in regions
16–20 and 21–30 can be N-homocysteinylated by HCTL.
According to these facts, we were interested to investigate the
effects of N-homocysteinylation in the mentioned regions on the
aggregation propensity and neurotoxicity of Ab1–42. In the present
study, we demonstrated that the homocysteinylation of lysine res-
idues increase the neurotoxicity of the Ab peptide by stabilizing
soluble oligomeric intermediates.2. Materials and methods
2.1. Materials
Human Ab1–42 was purchased from r-Peptide Company (USA).
The cell culturemedium (RPMI 1640), penicillin–streptomycin, fetal
bovine serum (FBS) and horse serum were purchased from Gibco
BRL (Life technology, Paisley, Scotland). The culture plates were ob-
tained fromNunc (Denmark). Ethidium bromide (EtBr) and acridine
orange (AO) were purchased from Pharmacia LKB Biotechnology
(Sweden). MTT [3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazo
liumbromide], thioﬂavin T (ThT), L-Hcy-thiolactone (HCTL), c-buty-
rolactone and 5,50-dithio-bis (2-nitrobenzoic acid) (DTNB) were
purchased from Sigma Chemicals Co. (Germany).
2.2. Peptide preparation and modiﬁcation
Peptide solution was prepared according to the manufacturer’s
instructions. Brieﬂy, Ab1–42was re-suspended in 1%NH4OHat a con-
centration of 1 mg/ml and sonicated for 1 min, then stored at70 C
until used. Ab1–42 has no free sulfydryl group andpossesses only two
lysine residues (Lys16 and Lys28)which can bemodiﬁed byHCTL. In
order to N-homocysteinylate Ab1–42, peptide solution was diluted
with phosphate buffer (50 mM, pH 7.4) containing 400 lM of HCTL
to 100 lM and incubated with gentle shaking at 37 C for 6 h. To
investigate the probable effect of lactone ring in HCTL on the aggre-
gation process, c-butyrolactone (analogue of HCTL) was used in
similar concentrations and incubation times. Control experiment
was carried out in the absence of lactone compounds. At the end
of incubation, the specimens were dialyzed, using cellulose acetate
membrane with the molecular weight cut-off of 1-kDa, to remove
different types of free lactones. In order to determine the extent of
modiﬁed peptide, the levels of peptide sulfhydryls were analyzed
using the Ellman’s test [33]. Brieﬂy, it is based on the reaction of
the thiolate anion (R–S) with Ellman’s reagent (DTNB2) where-
upon a mixed disulﬁde (R–S–TNB) and one equivalent of TNB2
is formed that exhibits intense light absorption at 412 nm. The
amount of free sulfhydryl groups per peptide molecule (amount ofmodiﬁed peptide) for the peptide pre-incubatedwith HCTLwas cal-
culated to be 0.94 ± 0.03. No absorption at 412 nmwas detected for
the control peptide and the peptide pre-incubated with c-butyro-
lactone as well. To prepare Ab1–42 ﬁbrils, pre-incubated peptide
solutionswere incubated at 37 C for aweek. At the indicated times,
the extent of ﬁbril formation was assayed by ThT ﬂuorescence and
electron microscopy, as described below.
2.3. Thioﬂavin T assay
Thioﬂavin T (ThT), a dye that speciﬁcally binds to b-sheet struc-
tures, is widely used for the identiﬁcation and quantiﬁcation of
amyloid ﬁbrils [34]. A 100 lM aqueous stock solution of ThT was
prepared and ﬁltered through a 0.2 lm ﬁlter. The different aged
samples of Ab1–42 were diluted in 10 mM phosphate buffer (pH
7.4) to a ﬁnal concentration of 5 lM. Then, 15 ll of stock ThT
was added to 140 ll of each test sample. Fluorescence intensity
was monitored immediately using a Varian-spectroﬂuorometer
(Model: Cary Eclipse) with the excitation and emission wave-
lengths of 450 and 482 nm, respectively.
2.4. Electron microscopy
The ultrastructural characteristics of Ab-aggregates were inves-
tigated by electron microscopy. To prepare the specimens for
transmission electron microscopy (TEM), 5 lL aliquot of each sam-
ple was spotted onto a formvar/carbon-coated copper grid and
incubated for 1 min. The TEM grids were then blotted and washed
twice in distilled H2O prior to negative staining with 2% uranyl ace-
tate for 1 min. Samples were examined using a Hu-12A TEM (Hit-
achi, Japan), operating at 75 kV.
2.5. Circular dichroism (CD) spectroscopy
Changes in secondary structure of different Ab1–42 samples
were analyzed during aggregation by circular dichroism (CD) spec-
troscopy. CD spectra were recorded on an Aviv model 215 Spectro-
polarimeter (Lakewood, NJ, USA). Measurements were performed
in the spectral range of 195–260 nm using a quartz cuvette (Hel-
ma) with a path length of 1 mm and a scan rate of 20 nm/min.
Investigation of secondary structure during aggregation was per-
formed at a peptide concentration of 40 lM. A composite buffer
containing 10 mM PB at pH 7.4 was prepared and its contribution
was subtracted in the CD spectra of Ab1–42 to give a normalized
spectrum. Spectra were converted from machine units in millide-
grees to delta epsilons.
2.6. Cell culture
PC12 rat pheochromacytoma cells, obtained from Pasteur Insti-
tute (Tehran, Iran), were cultured at a density of 1  105 cells/ml in
RPMI 1640 medium supplemented with 5% horse serum, 10% fetal
bovine serum, 100 lg/ml streptomycin and 100 U/ml penicillin,
and incubated at 37 C in the presence of 5% CO2.
2.7. Neurotoxicity assays
Metabolic activity of the assayed cells was measured by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction assay. PC12 rat pheochromacytoma cells were
chosen for assessing cytotoxicity because they have been identiﬁed
as sensitive to the toxic effects of Ab using MTT [35]. To examine
precisely the correlation between inhibition of MTT reduction
and cell death, both experiments were performed with the same
cultures. Cells were seeded at a density of 7500 cells/well in 96-
well plates in 100 ll of fresh medium. After 24 h, the cells were
Fig. 1. Time course of Ab1–42 ﬁbril formation monitored by ThT ﬂuorescence. Ab
samples (100 lM) incubated at various time intervals and then ThT solution was
added. Error bars represent the mean ± S.D. (n = 3). ⁄Signiﬁcantly different from
Ab1–42 control (P < 0.01).
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tion of 10 lM for 48 h. The media were collected for lactate
dehydrogenase (LDH) measurements. Then, 10 ll of 5 mg/ml
MTT solution was added to each well, and the plates were incu-
bated at 37 C for 4 h. The medium was removed and the formazan
crystals were dissolved in DMSO. After 18 h of incubation in a
humidiﬁed CO2 incubator, the absorbance at 570 nm was read
using a microplate reader (Expert 96, Asys Hitch, Ec Austria). Re-
sults were expressed as a percentage of the control values. Cell
death was assessed by release of LDH from cells. The LDH activity
was measured spectrophotometrically according to the manufac-
turer’s instructions (Pars Azmun, Iran).
2.8. Fluorescence microscopy
Morphological assessment of untreated and different Ab-treated
cells was performed using the acridine orange/ethidium bromide
double staining method [36]. PC12 cells (5  104 cells/well) were
seeded in 24-well plates. After 24 h, the cells were incubated with
and without different aged Ab1–42 samples at a ﬁnal concentration
of 10 lM for 48 h. After incubation, cells were washed with PBS
and stained with AO/EtBr solution (1:1 v/v) at a ﬁnal concentration
of 100 lg/ml. The nuclear morphology of the cells was assessed by
Axoscope 2 plus ﬂuorescence microscope (Zeiss, Germany). The
cells with condensed or fragmented nuclei were counted as apopto-
tic cells. All experiments were repeated three times and the number
of stained cells was counted in 10 randomly selected ﬁelds.
2.9. Statistical analysis
All values in the ﬁgures of present study indicate means ± stan-
dard deviation (S.D.), and all determinations were repeated three
times. The signiﬁcance differences between the means of the trea-
ted and untreated groups were calculated by unpaired Student’s t-
test and P-values less than 0.01 were considered signiﬁcant.Fig. 2. (A) Electron micrographs of negative-stained preparations of the different
Ab1–42 samples. The different peptides samples (100 lM) were incubated for 7 days
at 37 C. Fibrils formed by c-butyrolactone pre-incubated Ab1–42 () exhibited
morphology similar to that of Ab1–42 control (d). No ﬁbril formation was observed
in N-homocysteinylated Ab1–42 (N). (B) Far-UV CD spectra of different Ab1–42
samples at time 0 (0 h) and after a 7-day incubation. All the samples were measured
at a concentration of 40 lM. Data represent the mean ± S.D. (n = 3).3. Results and discussion
Chemical modiﬁcation is one of the most useful methods to
study protein structure–function relationships. Numerous studies
have shown that the tertiary structure and biological activity of
proteins are dependent on the physicochemical properties of their
constituent amino acids [37,38]. Therefore, enzymatic or non-
enzymatic chemical modiﬁcations of speciﬁc residues of a protein,
such as acetylation, ubiquitination, and phosphorylation would
result in signiﬁcant changes in its structure and function [39].
Previous studies have shown that stacking interactions between
two homologous regions in the key aggregation motif of Ab
(16KLVFF20) peptides and electrostatic interaction between
Lys28 and Glu22/Asp23 within each Ab peptide play a signiﬁcant
role in the molecular recognition and self-assembly processes that
lead to amyloid formation [25–32]. Therefore, any factor that dis-
rupts these interactions could potentially reduce or inhibit amyloid
formation.
In the present study we investigated the effects of N-homocy-
steinylation of Ab1–42, on the aggregation propensity and cellular
toxicity of Ab1–42 by using a variety of techniques such as ThT ﬂuo-
rescence, Far-UV CD and TEM as well as MTT and LDH assays.
Thioﬂavin T, a deﬁning probe for the identiﬁcation and mecha-
nistic study of amyloid ﬁbril formation, interacts with the
b-pleated sheet-containing amyloid ﬁbrils leading to an enhance-
ment in ThT ﬂuorescence. As shown in Fig. 1, c-butyrolactone
pre-incubated Ab1–42 showed no signiﬁcant difference in ﬂuores-
cence intensity compared to the control Ab1–42 sample at all incu-
bation times (freshly, 6, 12, 24, 48, 72, 120 hours and 7 days).However, N-homocysteinylation of Ab1–42 caused a pronounced in-
crease in lag time and inhibited around 50% of the b-sheet ﬁbril
formation almost at all incubation times, as compared with the
control Ab1–42 sample. These results indicated that chemical mod-
iﬁcation of lysine residues, decreased tendency of Ab1–42 to form
amyloid ﬁbrils.
To gain further detailed insight into the structural features of N-
homocysteinylated Ab1–42, the secondary structures changes dur-
ing aggregation were characterized by Far-UV CD spectroscopy.
Far-UV CD, probing the chiral environment of the amide group, is
very sensitive to small changes of the secondary structure in
protein aggregation. During aggregation process, Ab undergoes
conformational changes from random coil/a-helix to b-sheet struc-
ture [20,40]. As shown in Fig. 2B, immediately after incubation
(time 0), all samples display a strongly negative ellipticity reading
at 200 nm, indicating the presence of an unfolded state with ‘‘ran-
dom-coil properties’’. After the incubation time, control and c-
butyrolactone pre-incubated Ab1–42 display signiﬁcantly strong
characteristic absorbance of b-sheet structure around 215–
220 nm, with a continuous increase in signal at 218 nm, arising
from the stabilization of b-sheet structure. However, N-homocyste-
inylation of Ab1–42 attenuated the changes of the negative CD sig-
nals at 218 nm, suggesting that chemical modiﬁcation of lysine
residues inhibits b-sheet formation of Ab1–42 (Fig. 2B). These re-
sults were in agreement with ThT ﬂuorescence assay. The pro-
longed lag time and the attenuated conformational changes from
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signiﬁcant structural changes induced by N-homocysteinylation,
resulted in the stabilization of oligomeric aggregates [41,42].
In order to study the morphology of Ab aggregates, different
Ab1–42 samples were negatively stained, placed on copper grids
and examined by electron microscopy. As shown in Fig. 2A, incuba-
tion of control and c-butyrolactone pre-incubated Ab1–42 for 7 days
at 37 C, resulted in the ﬁbril formation, signiﬁcantly. In contrast,
chemical modiﬁcation of lysine residues reduced ﬁbril content of
Ab and increased the extent of oligomers, which was consistent
with ThT ﬂuorescence and CD spectroscopy results. These struc-
tural changes could be considered as a result of disruption of stack-
ing interactions and/or due to the elimination of the salt bridge
involved in stability of the b-turn. These results conﬁrmed impor-
tant role of lysine residues in Ab aggregation and amyloidogenesis
in AD [30,33].
Although amyloid ﬁbrils were previously considered to be cyto-
toxic, current experimental evidence suggest that soluble oligo-
meric intermediates are more toxic [16,21,22]. In order to study
the effect of structural changes on the cytotoxicity of Ab1–42, cell
viability and morphology experiments were carried out.
Metabolic activity of PC12 cells treated with different aged Ab1–
42 samples was determined at speciﬁed intervals of incubation
times using MTT assay. The data obtained by MTT assay indicated
that by prolongation of pre-incubation of N-homocysteinylated
Ab1–42, the viability of PC12 cells was decreased, time-dependently
(Fig. 3A). This reduction for the cells exposed to 72-h pre-incubated
N-homocysteinylated Ab1–42 was about 40% compared to the Ab-
treated control cells (Fig. 3A). Fresh Ab1–42 (10 lM) has almost no
impact on MTT reduction.
Increase in the plasma membrane permeability, resulted from
the formation of free radicals, is one of the mechanisms by which
Ab and/or its aggregation products induce neuronal death. The
crelease of the cytoplasmic enzyme LDH into culture medium is
used as a marker for cell membrane integrity. As shown inFig. 3. Toxicity of 10 lM different Ab1–42 samples to PC12 cells, at speciﬁed
intervals of incubation times, was determined using MTT (A) and LDH (B) assays.
The data were expressed as the percentage of values in untreated control cells and
each value represent the mean ± S.D. (n = 3). In the case of the LDH release assay,
total cellular LDH value (0.5% Triton X-100) was determined at time 0 and was
taken as 100%. ⁄Signiﬁcantly different from Ab1–42 control (P < 0.01).Fig. 3B, PC12 cells exposure to N-homocysteinylated Ab1–42
(10 lM) leads to the release of LDH to the culture medium by
about twofold, compared to the cells treated with aged control
Ab1–42. These results are in accordance with the ﬁndings obtained
from MTT assay. Based on the Neuronal viability assays, the chem-
ical modiﬁcation of lysine residues in the Ab enhanced the Ab-in-
duced cell viability loss and cell death. The decrease in MTT
reduction and the increase in LDH release were probably the con-
sequence of the high concentration of neurotoxic oligomers in the
aged N-homocysteinylated Ab1–42 sample.
It has been shown that various forms of Ab aggregates may acti-
vate different pathways in cell lines, resulting in either necrotic or
apoptotic cell death [43,44]. The mode of cell death was analyzed
with AO/EtBr dual staining with ﬂuorescence microscopy. In com-
parison with the untreated control cells, which are uniformly
stained green (Fig. 4A), apoptotic cells contain bright green dots
in their nuclei corresponding to nuclear DNA fragmentation [45].
According to the results obtained from AO/EtBr staining assay,
chemical modiﬁcation of Ab1–42 induced apoptotic cell death in
PC12 cell line. Quantitative analysis of the stained cells indicated
that the incubation with N-homocysteinylated Ab1–42 signiﬁcantly
elevated the extent of cell apoptosis up to 75% compared to 40%
observed among the cells exposed to aged control Ab1–42 (Fig. 4).
According to recent reports, N-homocysteinylation of the glob-
ular proteins can convert the protein structure into a partially
unfolded intermediate with a higher tendency to form aggregate
[46]. Ab is natively unfolded in monomeric state. According to
our results N-homocysteinylation dose not have signiﬁcant effect
on Ab secondary structure at zero time of incubation. Analyses
and computational studies indicate that amyloid aggregates share
a common, cross-beta structure highly enriched in b-sheet con-
tents [47–50]. Therefore, b-sheet propensity can inﬂuence the
structural properties of the aggregates and lead to a diverse set
of supramolecular assemblies. Our results suggest that N-homocy-
steinylation of Ab via a decrease in beta sheet propensity willFig. 4. Visualization of apoptotic cell death induced by different aged Ab1–42
samples. AO/EtBr double staining technique shows the PC12 cells untreated (A), and
treated with: c-butyrolactone pre-incubated Ab1–42 (B), Ab1–42 control (C) and N-
homocysteinylated Ab1–42 (D). The cells were stained after 48 h of incubation.
S. Khodadadi et al. / FEBS Letters 586 (2012) 127–131 131decrease oligomers elongation and/or ﬁbril formation and hence,
possibly leads to new toxic protoﬁbrils with low self-assembly
and high toxicity [41,42,46,51]. This study proposes a probable
mechanism for the correlation between hyperhomocysteinemia
and the progress of Alzheimer’s disease.
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